Shay Capital’s Soleno Therapeutics SLNO Stock Holding History

Shay Capital’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,200	Closed	-$2.11M	–	498
2025 Q2	$2.11M	Buy	+25,200	New	+$1.89M	0.24%	68

Other funds holding SLNO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Shay Capital's SLNO Position: Q1 2026 in Review

Shay Capital sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 4,600 shares — an estimated $213K sold.

Shay Capital first reported a position in SLNO in Q4 2025 and held it in 1 quarter. The position peaked at $213K in Q4 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

Shay Capital reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
Shay Capital sold 4,600 Soleno Therapeutics shares in Q1 2026, an estimated $213K.
Shay Capital first reported a position in Soleno Therapeutics in Q4 2025 and held it in 1 quarter.
Shay Capital's Soleno Therapeutics position peaked at $213K in Q4 2025.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Shay Capital's 13F filing for Q1 2026, filed 15 May 2026.